STAA Staar Surgical (STAA) Insider Trading, Ownership & Congress Trades
Medical Devices · Ophthalmic goods · CIK 0000718937
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
115
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $28.8K priced
Staar Surgical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for STAAR SURGICAL CO in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 31 earlier Form 4 trades (code P or S) here by this insider (31 buys), the last on Mar 12, 2026.
- -6.0% median (-2.3% mean) 90-day return after 23 previous buys.
- The trade is 2.0% of the 16,123,842 shares held after it.
- No other insider bought within 30 days.
- 115 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BROADWOOD CAPITAL INC bought about $5.9M of STAA on Mar 13, 2026; 115 funds added in the latest 13F quarter.Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 buys), the last on Mar 11, 2026.
- -6.5% median (-5.1% mean) 90-day return after 22 previous buys.
- The trade is 1.9% of the 15,807,825 shares held after it.
- No other insider bought within 30 days.
- 115 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BROADWOOD CAPITAL INC bought about $5.4M of STAA on Mar 12, 2026; 115 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 buys), the last on Mar 25, 2025.
- -7.1% median (-8.6% mean) 90-day return after 21 previous buys.
- The trade is 0.4% of the 15,508,393 shares held after it.
- No other insider bought within 30 days.
- 115 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BROADWOOD CAPITAL INC bought about $959.5K of STAA on Mar 11, 2026; 115 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Jan 8, 2026.
- -5.2% median (-9.5% mean) 90-day return after 12 previous buys.
- The trade is 0.2% of the 15,453,629 shares held after it.
- No other insider bought within 30 days.
- 115 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Bradsher Neal C bought about $606.0K of STAA on Jan 9, 2026; 115 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jan 7, 2026.
- -5.0% median (-9.8% mean) 90-day return after 11 previous buys.
- The trade is 0.0% of the 15,426,144 shares held after it.
- No other insider bought within 30 days.
- 115 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Bradsher Neal C bought about $71.1K of STAA on Jan 8, 2026; 115 funds added in the latest 13F quarter.116 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
115 funds bought in last quarter
more than 67% of Medical Devices
Revenue
-23.7% year over year
below 91% of Medical Devices
Margin
-33.6% net margin
below 62% of Medical Devices
Buybacks
$6.5M repurchased, FY to 2026-01-02
below 71% of Medical Devices
Short interest
14.3% of the float short (float per yahoo 2026-10-26) · 2.8 days to cover · settled 2026-09-30
more than 79% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch STAA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-16.1%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns STAA: institutional holders (13F)
13F holdings, latest reported quarter
16,123,842 sh
$462.6M
6,731,154 sh
$193.1M
4,175,748 sh
$119.8M
3,257,130 sh
$93.4M
2,437,446 sh
$69.9M
Congress trades in STAA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
STAA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
STAA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.4M position · as of 2026-06-30
1.6%
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$400.2K position · as of 2026-06-30
1.3%
Invesco S&P SmallCap Health Care ETF
$1.0M position · as of 2026-05-31
0.8%
Burney U.S. Equity Select ETF
$3.1M position · as of 2026-07-31
0.5%
Burney U.S. Factor Rotation ETF
$2.6M position · as of 2026-07-31
0.5%
Amplify Etho Climate Leadership U.S. ETF
$842.7K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Thomas GFrinzi
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$7.8M
$2.7M
$2.6M
-69%
-5%
2023
$10.2M
$6.4M
$2.7M
-61%
-11%
2022
$6.5M
$1.0M
$2.1M
-39%
-11%
2021
$5.5M
$11.6M
$1.9M
+15%
+11%
2020
$3.0M
$12.7M
$1.7M
+130%
+32%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 115 funds added last quarter. Each figure is a federal filing, dated the day it went public.
STAA financials
Revenue growth
-23.7%
XBRL, annual
Net margin
-33.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$339.6M
four quarters, 2025-06-28 to 2026-07-03
Revenue, TTM STAA
| FY Jan 2026 | $239.4M |
| FY Dec 2024 | $313.9M |
| FY Dec 2023 | $322.4M |
| FY Dec 2023 | $322.4M |
| FY Dec 2022 | n/a |
| Jul 2026 | $93.5M |
| Apr 2026 | $93.5M |
| Jan 2026 | $57.8M |
| Sep 2025 | $94.7M |
| Jun 2025 | $44.3M |
| Mar 2025 | $42.6M |
| Dec 2024 | $49.0M |
| Sep 2024 | $88.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+1.1%
net income over revenue, 2025-06-28 to 2026-07-03
Net margin, TTM STAA
| FY Jan 2026 | -33.6% |
| FY Dec 2024 | -6.4% |
| FY Dec 2023 | +6.6% |
| FY Dec 2023 | +6.6% |
| FY Dec 2022 | n/a |
| Jul 2026 | +8.6% |
| Apr 2026 | +5.6% |
| Jan 2026 | -31.7% |
| Sep 2025 | +9.4% |
| Jun 2025 | -37.9% |
| Mar 2025 | -127.3% |
| Dec 2024 | -69.9% |
| Sep 2024 | +11.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$6.7M
operating cash flow minus capex, 2025-06-28 to 2026-07-03
Free cash flow, TTM STAA
| FY Jan 2026 | -$40.0M |
| FY Dec 2024 | -$7.7M |
| FY Dec 2023 | -$3.6M |
| FY Dec 2023 | -$3.6M |
| FY Dec 2022 | $17.6M |
| Jul 2026 | $19.2M |
| Apr 2026 | -$22.1M |
| Jan 2026 | -$5.6M |
| Sep 2025 | $1.8M |
| Jun 2025 | -$29.0M |
| Mar 2025 | -$7.2M |
| Dec 2024 | -$5.1M |
| Sep 2024 | -$2.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.1%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on equity STAA
| FY Jan 2026 | -21.7% |
| FY Dec 2024 | -5.2% |
| FY Dec 2023 | +5.9% |
| FY Dec 2023 | +5.9% |
| FY Dec 2022 | +13.3% |
| Jul 2026 | +1.1% |
| Apr 2026 | -6.0% |
| Jan 2026 | -21.7% |
| Sep 2025 | -24.6% |
| Jun 2025 | -25.6% |
| Mar 2025 | -19.1% |
| Dec 2024 | -5.2% |
| Sep 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.8%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on assets STAA
| FY Jan 2026 | -16.7% |
| FY Dec 2024 | -4.0% |
| FY Dec 2023 | +4.7% |
| FY Dec 2023 | +4.7% |
| FY Dec 2022 | +10.4% |
| Jul 2026 | +0.8% |
| Apr 2026 | -4.6% |
| Jan 2026 | -16.7% |
| Sep 2025 | -19.4% |
| Jun 2025 | -20.0% |
| Mar 2025 | -15.0% |
| Dec 2024 | -4.0% |
| Sep 2024 | +4.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 78%, not meaningful
Return on invested capital STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+3.5%
operating income (EBIT proxy) over average of 2025-06-27 and 2026-07-03 minus current liabilities
Return on capital employed STAA
| FY Jan 2026 | -22.3% |
| FY Dec 2024 | -2.9% |
| FY Dec 2023 | +7.1% |
| FY Dec 2023 | +7.1% |
| FY Dec 2022 | +13.2% |
| Jul 2026 | +3.5% |
| Apr 2026 | -6.8% |
| Jan 2026 | -22.3% |
| Sep 2025 | -22.4% |
| Jun 2025 | -26.6% |
| Mar 2025 | -16.5% |
| Dec 2024 | -2.9% |
| Sep 2024 | +5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
282.63x
close 2026-10-23 over four quarters of diluted EPS, 2025-06-28 to 2026-07-03
P/E, trailing STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 72.58x |
| FY Dec 2023 | 72.58x |
| FY Dec 2022 | 61.44x |
| Jul 2026 | 347.38x |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 84.61x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.6%
TTM free cash flow over market value at close 2026-10-23
FCF yield STAA
| FY Jan 2026 | -3.4% |
| FY Dec 2024 | -0.6% |
| FY Dec 2023 | -0.2% |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | +0.8% |
| Jul 2026 | -0.5% |
| Apr 2026 | -5.5% |
| Jan 2026 | -3.4% |
| Sep 2025 | -3.0% |
| Jun 2025 | -5.2% |
| Mar 2025 | -3.6% |
| Dec 2024 | -0.6% |
| Sep 2024 | +1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing STAA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.00x |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 8.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-01 | 2024-12 | 2023-12 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | n/a | $322.4M |
| Gross profit | $182.4M | $239.6M | n/a | $252.7M |
| Operating income | -$91.7M | -$12.6M | n/a | $28.1M |
| Net income | -$80.4M | -$20.2M | $21.3M | $21.3M |
| EPS (diluted) | -1.62 | -0.41 | n/a | 0.43 |
| Operating cash flow | -$34.2M | $15.7M | n/a | $14.6M |
| Cash | $153.2M | $144.2M | n/a | $183.0M |
| Buybacks | $6.5M | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
STAA Stock Sonar score 4/7 axes
Find similar shapesCompareSTAA ranks highest on profitability (71st percentile) and institutional and government (67th), and lowest on growth (9th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
